Healthcare - Biotechnology - NASDAQ - US
$ 4.76
-5.18 %
$ 326 M
Market Cap
-1.25
P/E
INCOME STATEMENT
381 M
REVENUE
38.8 M
OPERATING INCOME
49.3 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Amylyx Pharmaceuticals, Inc.
| Revenue | 381 M |
| Cost Of Revenue | 25.4 M |
| Gross Profit | 355 M |
| Operating Expenses | 317 M |
| Operating Income | 38.8 M |
| Other Expenses | -10.5 M |
| Net Income | 49.3 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| REVENUE | |||||
| Revenue | 380.8 | 22.2 | 0.3 | 0.7 | 1.4 |
| GROSS PROFIT | |||||
| Cost Of Revenue | 25.4 | 3.0 | 52 K | 24.6 | 11.9 |
| Gross Profit | 355.3 | 19.2 | 0.2 | (23.9) | (10.5) |
| OPERATING INCOME | |||||
| Operating Expenses | 316.5 | 220.6 | 82.7 | 39.0 | 13.6 |
| Selling, General and Administrative Expenses | 188.4 | 127.1 | 38.9 | 15.1 | 3.1 |
| Research and Development Expenses | 128.2 | 93.5 | 44.0 | 24.6 | 11.9 |
| Operating Income | 38.8 | (201.3) | (82.7) | (39.0) | (13.6) |
| PRE-TAX INCOME | |||||
| Interest Income Expense | 0 | 4.3 | 0 | 2.3 | 1.3 |
| Total Other Income | 15.5 | 3.7 | (5.2) | (3.3) | (0.2) |
| Pre-Tax Income | 54.3 | (197.6) | (87.9) | (42.3) | (13.7) |
| NET INCOME | |||||
| Tax Provision | 5.0 | 0.8 | 52 K | 2.6 | 1.1 |
| Net Income | 49.3 | (198.4) | (87.9) | (44.8) | (14.8) |
| EPS | 0.73 | 2.98 | 1.52 | 0.79 | 0.26 |